BRAF V600E and survival benefit of anti-EGFR monoclonal antibody (mAb) therapy for metastatic colorectal cancer (mCRC): A meta-analysis.

被引：0
|
作者：
Sorich, Michael
Rowland, Andrew
Dias, Mafalda
McKinnon, Ross Allan
Kichenadasse, Ganessan
Wiese, Michael
Karapetis, Christos Stelios
机构：
[1] Flinders Univ S Australia, Adelaide, SA 5001, Australia
[2] Flinders Univ S Australia, Flinders Med Ctr, Adelaide, SA 5001, Australia
[3] Univ S Australia, Adelaide, SA 5001, Australia
[4] Flinders Univ S Australia, Flinders Ctr Innovat Canc, Adelaide, SA 5001, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e14605
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14605
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis
    Yuan, Zi-Xu
    Wang, Xiao-Yan
    Qin, Qi-Yuan
    Chen, De-Feng
    Zhong, Qing-Hua
    Wang, Lei
    Wang, Jian-Ping
    PLOS ONE, 2013, 8 (06):
  • [22] Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study
    Eiji Shinozaki
    Takayuki Yoshino
    Kentaro Yamazaki
    Kei Muro
    Kensei Yamaguchi
    Tomohiro Nishina
    Satoshi Yuki
    Kohei Shitara
    Hideaki Bando
    Sachiyo Mimaki
    Chikako Nakai
    Koutatsu Matsushima
    Yutaka Suzuki
    Kiwamu Akagi
    Takeharu Yamanaka
    Shogo Nomura
    Satoshi Fujii
    Hiroyasu Esumi
    Masaya Sugiyama
    Nao Nishida
    Masashi Mizokami
    Yasuhiro Koh
    Yukiko Abe
    Atsushi Ohtsu
    Katsuya Tsuchihara
    British Journal of Cancer, 2017, 117 : 1450 - 1458
  • [23] Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’
    Andrew Rowland
    Mafalda M Dias
    Michael D Wiese
    Ganessan Kichenadasse
    Ross A McKinnon
    Christos S Karapetis
    Michael J Sorich
    British Journal of Cancer, 2015, 113 : 1635 - 1635
  • [24] Clinicopathological features, efficacy of anti-EGFR therapy, and survival outcomes in patients with BRAF non-V600 mutated metastatic colorectal cancer.
    Kotani, Daisuke
    Mondaca, Sebastian
    Parikh, Aparna
    Bando, Hideaki
    Van Seventer, Emily
    Taniguchi, Hiroya
    Yoshino, Takayuki
    Corcoran, Ryan Bruce
    Yaeger, Rona
    Ebi, Hiromichi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [25] Reply: Comment on 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'
    Rowland, Andrew
    Dias, Mafalda M.
    Wiese, Michael D.
    Kichenadasse, Ganessan
    McKinnon, Ross A.
    Karapetis, Christos S.
    Sorich, Michael J.
    BRITISH JOURNAL OF CANCER, 2015, 113 (11) : 1635 - 1635
  • [26] Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation
    Zaina T. Al-Salama
    Drugs, 2021, 81 : 849 - 856
  • [27] Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation
    Al-Salama, Zaina T.
    DRUGS, 2021, 81 (07) : 849 - 856
  • [28] Clinical translation of predictive markers for anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer
    Rowland, Andrew
    Karapetis, Christos S.
    Mangoni, Arduino A.
    Wiese, Michael D.
    Kichenadasse, Ganessan
    McKinnon, Ross A.
    Sorich, Michael J.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S31 - S34
  • [29] Prognostic impact of BRAF V600E mutation in patients with non-metastatic colorectal cancer with microsatellite instability: A systematic review and meta-analysis.
    Manthravadi, Sashidhar
    Sun, Weijing
    Saeed, Anwaar
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'
    Dankner, Matthew
    Rose, April A. N.
    BRITISH JOURNAL OF CANCER, 2018, 118 (09) : 1276 - 1277
12345